EUVIMEDEUVIMED entdecken
VergleichsstudieOpen Access · CC BY-NC 4.0

Apixaban Versus Rivaroxaban After Spontaneous Intracranial Hemorrhage in Atrial Fibrillation: A Propensity Score-Matched TriNetX Study

Muhammad Abdullah Naveed, Muhammad Omer Rehan, Hamayel Qadir, Muhammad Hasan, Syed Husain Farhan, Ahila Ali, Syed Ahmed Farhan, Maham Abbasi, Syed Shoreh Qazi, Wael Almahmeed, Sivaram Neppala, Muhammad Bilal Munir iD

Clinical and Applied Thrombosis/Hemostasis · 2026-01 · 32

DOI: 10.1177/10760296261503682 ↗

Kurz gefasst

Vergleichsstudie in der Zeitschrift Clinical and Applied Thrombosis/Hemostasis, online erschienen am 30.10.2026. Verfasst von Muhammad Abdullah Naveed und 11 weiteren Autor:innen. Beteiligte Einrichtung: Department of Cardiology, Dow Medical College, Dow University of Health Sciences, Karachi, Pakistan. Hauptthemen laut MEDLINE: Atrial Fibrillation, Rivaroxaban, Pyrazoles, Pyridones. Die Arbeit nennt 34 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Survivors of spontaneous intracranial hemorrhage (ICH) with atrial fibrillation (AF) face competing risks of thromboembolism and recurrent bleeding. Evidence directly comparing individual direct oral anticoagulants after resumption is limited.

Methods

Using the TriNetX Global Collaborative Network, we conducted a retrospective cohort study of adults with AF who restarted apixaban or rivaroxaban after spontaneous ICH. The index date was DOAC resumption, and cohorts were matched 1:1 using propensity scores. Recurrent spontaneous ICH was assessed at 30, 90, 180, and 365 days. One-year secondary outcomes were ischemic stroke, all-cause mortality, major bleeding, and gastrointestinal bleeding. Cox models produced hazard ratios (HRs) with 95% confidence intervals, with log-rank testing.

Results

At 1 year, recurrent spontaneous ICH occurred in 141 (34.9%) apixaban-treated and 135 (33.4%) rivaroxaban-treated patients (HR 1.076, 95% CI 0.850-1.363; P = 0.542). No significant differences were detected at 30, 90, or 180 days. One-year ischemic stroke (HR 1.109, 95% CI 0.863-1.424), all-cause mortality (HR 1.336, 95% CI 0.937-1.903), major bleeding (HR 1.074, 95% CI 0.861-1.339), and gastrointestinal bleeding (HR 1.480, 95% CI 0.844-2.597) also did not differ. A day 31-365 sensitivity analysis was consistent (HR 1.02, 95% CI 0.77-1.36; P = 0.868) .

Conclusions

In this propensity score-matched real-world cohort, no statistically significant differences were detected between apixaban and rivaroxaban for recurrent spontaneous ICH or major clinical outcomes after anticoagulation resumption. These findings concern the choice of agent among patients in whom resumption has already been decided; anticoagulation after spontaneous ICH remains an unproven strategy, and enrolment in randomized trials is preferred where available.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Atrial FibrillationRivaroxabanPyrazolesPyridonesIntracranial HemorrhagesHumansFemaleMalePropensity ScoreRetrospective StudiesAgedFactor Xa InhibitorsMiddle Aged

Stichwörter der Autor:innen

Atrial fibrillationTriNetXapixabandirect oral anticoagulantintracranial hemorrhagepropensity scorerecurrent hemorrhagerivaroxaban

Substanzen

RivaroxabanapixabanPyrazolesPyridonesFactor Xa Inhibitors

Autor:innen und Institutionen

  • Department of Cardiology, Dow Medical College, Dow University of Health Sciences, Karachi, Pakistan.
  • Department of Internal Medicine, McLaren Greater Lansing Hospital, Lansing, MI, USA.
  • Department of Internal Medicine, Capital Health Regional Medical Center, Trenton, NJ, USA.
  • Department of Medicine, OhioHealth, Columbus, OH, USA.
  • Department of Cardiology, Heart Vascular and Thoracic Institute, Cleveland Clinic Abu Dhabi, Abu Dhabi, United Arab Emirates.
  • Division of Cardiology, The University of Texas Health Sciences Center, San Antonio, TX, USA.

ORCID-Profile: Muhammad Bilal Munir

Zitieren

APA

Naveed, M. A., Rehan, M. O., Qadir, H., Hasan, M., Farhan, S. H., Ali, A., Farhan, S. A., Abbasi, M., Qazi, S. S., Almahmeed, W., Neppala, S., & Munir, M. B. (2026). Apixaban Versus Rivaroxaban After Spontaneous Intracranial Hemorrhage in Atrial Fibrillation: A Propensity Score-Matched TriNetX Study. Clinical and Applied Thrombosis/Hemostasis, 32. https://doi.org/10.1177/10760296261503682

Vancouver

Naveed MA, Rehan MO, Qadir H, Hasan M, Farhan SH, Ali A, et al. Apixaban Versus Rivaroxaban After Spontaneous Intracranial Hemorrhage in Atrial Fibrillation: A Propensity Score-Matched TriNetX Study. Clinical and Applied Thrombosis/Hemostasis. 2026;32. doi:10.1177/10760296261503682

BibTeX
@article{Naveed2026,
  author = {Naveed, Muhammad Abdullah and Rehan, Muhammad Omer and Qadir, Hamayel and Hasan, Muhammad and Farhan, Syed Husain and Ali, Ahila and Farhan, Syed Ahmed and Abbasi, Maham and Qazi, Syed Shoreh and Almahmeed, Wael and Neppala, Sivaram and Munir, Muhammad Bilal},
  title = {Apixaban Versus Rivaroxaban After Spontaneous Intracranial Hemorrhage in Atrial Fibrillation: A Propensity Score-Matched TriNetX Study},
  journal = {Clinical and Applied Thrombosis/Hemostasis},
  year = {2026},
  volume = {32},
  doi = {10.1177/10760296261503682}
}
Kostenlos starten →